Muscle invasive bladder cancer: Prognostic factors, follow-up and treatment of relapses

Hernández-Fernández, C.; Herranz-Amo, F.; Moralejo-Gárate, M.; Subirá-Ríos, D.; Caño-Velasco, J.; Bernardos, G. Barbas

doi:10.1016/j.acuroe.2016.07.010

Cited by 3 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Plenty of prognostic factors for different cancers existed in current references, such as breast cancer ( 37 , 38 ), bladder cancer ( 39 , 40 ), RCC ( 41 ), colorectal cancer ( 42 ), lung cancer and so on. The researchers have proved some clinical prognostic factors, mainly tumor staging and performance status (PS) ( 43 ).…”

Section: Discussionmentioning

confidence: 99%

Serum amyloid A protein in cancer prognosis: a meta-analysis and systematic review

Lai¹,

Li²,

Gao³

2021

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: Published studies showed divergent results of the prognostic value of serum amyloid A protein (SAA) in patients with different cancers. Therefore, we conducted this meta-analysis so as to assess the association between SAA and cancer prognosis.Methods: A comprehensive search was conducted to identify the literatures working over SAA and survival in patients with cancers published until January 2020. Sufficient data for assessing overall survival in cancers were extracted descriptively and quantitatively from the studies and a pooled odds ratio was calculated using the Mantel-Haenszel fixed-effect or random-effect model.Results: Ten eligible papers were identified by two reviewers independently, including 4 studies that evaluated renal cell carcinoma (RCC), 2 studies evaluated lung cancer and the other 3 studies evaluated melanoma, gastric cancer and different cancers. Elevated SAA expression and shorter overall survival (OS) had a statistically significant relation [pooled 1-year OR was 5.07, 95% confidence interval (CI), 3.71-6.94, Q=9.15, I 2 =0%; pooled 3-year OR was 4.21, 95% CI, 3.18-5.56, Q=14.94, I 2 =46%; pooled 5-year OR was 5.69, 95% CI, 2.66-12.18, Q=24.83, I 2 =80%]. Subgroup analysis of RCC patients showed remarkable association between SAA and shorter OS (pooled 1-year OR =4.76, 95% CI, 3.00-7.56, Q=4.18, I 2 =4%; pooled 3-year OR =4.89, 95% CI, 3.06-7.81, Q=2.88, I 2 =0%).Conclusions: High SAA status is correlated with an unfavorable OS in different cancers, especially in RCC, and digestive cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum amyloid A protein in cancer prognosis: a meta-analysis and systematic review

Lai¹,

Li²,

Gao³

2021

Transl Cancer Res TCR

View full text Add to dashboard Cite

show abstract

“…While around 80% patients were initially diagnosed with non-muscle invasive bladder cancer (NMIBC) ( 2 ), over 45% of them experienced tumor recurrence within 2 years and 6% worsen with increased tumor grade. Additionally, 10% of the NMIBC patients may progress to muscle invasive bladder cancer (MIBC) ( 3 ), of whom approximately 50% were threatened by remote metastasis even though radical cystectomy has been performed ( 4 , 5 ). Therefore, patients with bladder cancer require long-term monitoring and surveillance.…”

Section: Introductionmentioning

confidence: 99%

Microfluidic Assaying of Circulating Tumor Cells and Its Application in Risk Stratification of Urothelial Bladder Cancer

Cheng

Chen

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Bladder cancer is characterized by its frequent recurrence and progression. Effective treatment strategies need to be based on an accurate risk stratification, in which muscle invasiveness and tumor grade represent the two most important factors. Traditional imaging techniques provide preliminary information about muscle invasiveness but are lacking in terms of accuracy. Although as the gold standard, pathological biopsy is only available after the surgery and cannot be performed longitudinally for long-term surveillance. In this work, we developed a microfluidic approach that interrogates circulating tumor cells (CTCs) in the peripheral blood of bladder cancer patients to reflect the risk stratification of the disease. In a cohort of 48 bladder cancer patients comprising 33 non-muscle invasive bladder cancer (NMIBC) cases and 15 muscle invasive bladder cancer (MIBC) cases, the CTC count was found to be considerably higher in the MIBC group compared with the NMIBC group (4.67 vs. 1.88 CTCs/3 mL, P=0.019), and was significantly higher in high-grade bladder cancer patients verses low-grade bladder cancer patients (3.69 vs. 1.18 CTCs/3mL, P=0.024). This microfluidic assay of CTCs is believed to be a promising complementary tool for the risk stratification of bladder cancer.

show abstract

“…Usually, human bladder carcinomas are superficial tumors (70% of cases) and are classified as non-muscle-invasive bladder carcinomas (NMIBCs) (11). Though NMIBC presents a good prognosis, muscle-invasive bladder carcinoma is considered a therapeutic challenge (11,12). Thus, in the human literature, muscle-invasive bladder carcinoma has been the focus of recent studies.…”

Section: Introductionmentioning

confidence: 99%

“…Since during cystoscopy a superficial small piece of tissue is collected from different areas, it is not usually possible to have tumor specimens containing deep layers, such as the muscular layers. In addition, human and canine bladder carcinoma can invade adjacent tissues and organs such as the ureter, prostatic urethra, and prostate gland (12).…”

Section: Introductionmentioning

confidence: 99%

A Comparative Meta-Analysis and in silico Analysis of Differentially Expressed Genes and Proteins in Canine and Human Bladder Cancer

et al. 2020

View full text Add to dashboard Cite

Canine and human bladder cancer present similar anatomical, morphological, and molecular characteristics, and dogs can be considered a model for human bladder cancer. However, the veterinary literature lacks information regarding cross-validation analysis between human and canine large-scale data. Therefore, this research aimed to perform a meta-analysis of the canine literature on bladder cancer, identifying genes and proteins previously evaluated in these studies. In addition, we also performed a cross-validation of the canine transcriptome data and the human data from The Cancer Genome Atlas (TCGA) to identify potential markers for both species. The meta-analysis was performed using the following indexing terms: “bladder” AND “carcinoma” AND “dog” in different international databases, and 385 manuscripts were identified in our initial search. Then, several inclusion criteria were applied, and only 25 studies met these criteria. Among these studies, five presented transcriptome data, and 20 evaluated only isolated genes or proteins. Regarding the studies involving isolated protein analysis, the HER-2 protein was the most studied (3/20), followed by TAG-72 (2/20), COX-2 (2/20), survivin (2/20), and CK7 (2/20), and the remaining nine studies evaluated one isolated protein each. Regarding the cross-validation analysis of human and canine transcriptome data, we identified 35 dysregulated genes, including ERBB2, TP53, EGFR , and E2F2 . Our results demonstrate that the canine literature on bladder cancer previously focused on the evaluation of isolated markers with no association with patient survival. This limitation may be related to the lack of a homogenous protocol for treating patients and the lack of follow-up during treatment. In addition, the lack of information regarding tumor muscle invasion can be considered an important limitation when comparing human and canine bladder tumors. Our in silico analysis involving canine and human transcriptome data provided several genes with the potential to be markers for both human and canine bladder tumors, and these genes should be considered for future studies on canine bladder cancer.

show abstract

Muscle invasive bladder cancer: Prognostic factors, follow-up and treatment of relapses

Cited by 3 publications

References 30 publications

Serum amyloid A protein in cancer prognosis: a meta-analysis and systematic review

Serum amyloid A protein in cancer prognosis: a meta-analysis and systematic review

Microfluidic Assaying of Circulating Tumor Cells and Its Application in Risk Stratification of Urothelial Bladder Cancer

A Comparative Meta-Analysis and in silico Analysis of Differentially Expressed Genes and Proteins in Canine and Human Bladder Cancer

Contact Info

Product

Resources

About